The properties of rhodiola rosea (also spelled rodiola) and its documented benefits have made this adaptogenic plant native to arctic and alpine regions (Siberia, Scandinavia, the high-altitude Pyrenees) one of the adaptogens with the largest number of published clinical trials in humans. Rhodiola rosea has traditionally been used to support resistance to physical and mental stress, particularly with regard to stress-related mental fatigue, cognitive performance under pressure and mild to moderate symptoms of low mood. The reference standardized form in research is the extract at 3% rosavins and 1% salidrosides, the two main bioactive compounds of the root. This page covers what rhodiola rosea is used for, its properties, how it works, the studied doses, the precautions and where it fits within the Pleniage portfolio.
What is rhodiola?
Rhodiola (Rhodiola rosea, also known as "golden root" or "arctic root") is a perennial plant of the Crassulaceae family. It grows naturally in cold-climate, high-altitude regions — Siberia, Scandinavia, Northern Europe, the high-altitude Pyrenees, Asian mountains. The part of the plant used in supplementation is the root, where the main bioactive compounds: rosavins and salidrosides are concentrated.
Traditionally rhodiola has been used in Scandinavian and Russian folk medicine as a tonic to support physical and mental resistance under high-demand conditions (extreme climate, military fatigue, prolonged working days). In modern research it is classified among the adaptogens, alongside ashwagandha, Asian ginseng (Panax ginseng) and other plants with a profile of modulating the physiological response to stress.
Before you start: contexts where you should consult first
Before considering supplementation with rhodiola, it is advisable to identify four contexts where prior medical assessment is necessary:
- Pregnancy and breastfeeding: contraindicated as a general precaution in the absence of sufficient human data.
- Bipolar disorder: contraindicated due to the theoretical risk of precipitating manic episodes through the activating component.
- Prescribed antidepressant treatment: rhodiola may be considered as an adjunct under psychiatric supervision, never as a substitute for the medical regimen.
- Relevant chronic medication (anticoagulants, antihypertensives, CYP2D6/3A4/2C9 substrates): consult a doctor or pharmacist beforehand.
For all other profiles without specific contraindications, the following sections explain standardization, mechanism, clinical evidence and a reasonable usage regimen.
Standardization 3% rosavins / 1% salidrosides: why it matters
Not all commercial rhodiolas are equivalent. The differences between extracts can be substantial and affect the ability to extrapolate the data from published clinical trials.
- Standardization at 3% rosavins and 1% salidrosides: this is the concentration used in most of the relevant clinical trials and the one considered the reference in professional formulation. The 3:1 ratio (rosavins:salidrosides) reflects the natural profile of Rhodiola rosea and distinguishes this species from other rhodiolas with different profiles (Rhodiola crenulata, for example, has a profile richer in salidrosides and lower in rosavins).
- Rhodiola rosea vs other species of the genus: the Rhodiola genus includes more than 200 species. Rhodiola rosea is the only one with a large body of clinical research in humans. Other species (R. crenulata, R. kirilowii, R. quadrifida) have been used in traditional Chinese/Tibetan medicine but have less modern clinical evidence.
- Analytical verification: premium extracts provide certificates of analysis confirming the declared concentrations of rosavins and salidrosides by HPLC.
The practical consequence is that the results of the published clinical trials were obtained specifically with R. rosea extracts standardized to 3% rosavins / 1% salidrosides; extracts with different bioactive profiles (other species of the genus or lower standardizations) have their own activity profile and the evidence for each should be checked.
How it works: adaptogenic profile and stress modulation
The concept of adaptogen was formulated in the USSR in the 1940s by the pharmacologist Nikolai Lazarev and developed by Israel Brekhman. It defines natural substances with three pharmacological features:
- Bidirectional modulation of the physiological response to stress: they tend to normalize parameters whether they are elevated or low.
- Relative innocuousness in prolonged use at usual doses.
- Nonspecific improvement of resistance to physical, chemical and biological stressors.
Rhodiola fits this profile. The mechanisms described in clinical and preclinical research are several:
- Modulation of the HPA axis: studies document attenuation of salivary and serum cortisol in people with chronic stress after supplementation with standardized rhodiola extract.
- Effects on monoaminergic neurotransmitters: in preclinical models, rhodiola modulates the activity of serotonin, dopamine and noradrenaline in specific brain regions. The clinical translation of this mechanism has been used to underpin the trials in mild to moderate low mood.
- Activation of cellular stress-response proteins such as Hsp70 (heat shock protein 70), involved in cellular resistance to multiple stressors.
- Modulation of AMPK and mTOR activity (preclinical data), with possible implications for cellular energy metabolism and autophagy.
Clinical evidence: mental fatigue, cognition and mood
The largest body of clinical evidence in humans on rhodiola covers three related areas:
Stress-related mental fatigue
The trial by Olsson and colleagues published in Planta Medica in 2009 studied 60 adults with stress-related fatigue, assigned to receive 576 mg/day of standardized rhodiola extract (SHR-5) or placebo for 28 days. The rhodiola group documented significant improvements in validated scales of fatigue (Pines Burnout Inventory) and of concentration capacity compared with placebo.
Cognitive performance under pressure
The trial by Spasov and colleagues published in Phytomedicine in 2000 studied medical students during an exam period (a situation of sustained cognitive demand), assigned to receive standardized rhodiola extract or placebo for 20 days. The rhodiola group documented improvements in cognitive performance tasks and in subjective well-being during the exam period.
Mild to moderate low mood
Rhodiola has been investigated in mild to moderate depressive presentations with positive results on validated scales. The trial by Darbinyan and colleagues published in Nordic Journal of Psychiatry in 2007 documented improvements on validated scales with SHR-5 extract in patients with mild to moderate depression. The trial by Mao and colleagues published in Phytomedicine in 2015 compared rhodiola (340 mg/day) with sertraline (50 mg/day) in patients with mild to moderate depression over 12 weeks: both interventions showed significant improvements, with sertraline presenting a greater effect size on the HAM-D scale and rhodiola a substantially better adverse-effect profile and a reasonable proportion of responders. This positions it as a reasonable option in mild presentations under medical supervision. In moderate or severe presentations where the doctor decides the main regimen, rhodiola may be considered as an adjunct.
Studied doses and time of day
The doses investigated in the main clinical trials with standardized rhodiola (3% rosavins / 1% salidrosides) range between 200 mg and 600 mg per day, in a single intake or split into two. The dose of 200-400 mg/day is the most used in commercial formulation and the most studied in trials on mental fatigue and cognition.
The time of day is important for a specific reason:
- Morning or pre-cognitive-activity intake: rhodiola may have a slightly activating component in some people, which is why late-evening intake is discouraged. The most used regimen is breakfast and/or the midday meal.
- Avoid intake 4-6 hours before sleep: in sensitive people it may interfere with falling asleep.
- Minimum duration of use: effects on fatigue and cognition are typically documented from 2-4 weeks of continued use. Rhodiola allows cycles of 8-12 weeks with rest periods of 2-4 weeks, although it has also been used in prolonged continued use in trials without relevant safety problems.
Rhodiola vs other adaptogens (ashwagandha, panax)
The main adaptogens with a body of clinical evidence in humans are three:
- Rhodiola (Rhodiola rosea 3:1): profile oriented toward mental fatigue and cognition under pressure. Slightly activating component. Morning/midday intake.
- Ashwagandha (Withania somnifera KSM-66): profile oriented toward cortisol, calm and sleep. No activating component. Flexible intake (morning or evening; evening if the focus is sleep). To learn more, see the Ashwagandha KSM-66 page.
- Asian ginseng (Panax ginseng): profile oriented toward energy and physical performance. Activating component more marked than rhodiola. Less specific calming profile.
The choice between adaptogens depends on the desired usage profile. Rhodiola fits especially in profiles where mental fatigue with a cognitive component predominates (long days with sustained mental demand, exam periods, recovery after illness). Ashwagandha is preferable when activation of the HPA axis with elevated cortisol and difficulty falling asleep predominates. The two can be combined — that is the rationale of the PRO CALM+ formula that includes them together.
Safety, tolerability and side effects
Rhodiola has a very favorable safety profile at usual doses in healthy adults. The available clinical trials document an incidence of adverse effects comparable to placebo, with effects described as mild and self-limiting.
Infrequent adverse effects
- Mild activation / difficulty falling asleep: especially with evening doses in sensitive people. Resolvable by switching to morning/midday intake.
- Mild headache: sporadically reported in clinical trials.
- Dry mouth: uncommon.
- Irritability or a feeling of "over-activation": may appear with high doses (>400 mg) in people sensitive to stimulants.
How to choose a rhodiola supplement
- Correct species: verified Rhodiola rosea (not other rhodiolas such as R. crenulata).
- Standardization 3% rosavins / 1% salidrosides: the concentration used in most published clinical trials.
- Dose consistent with the evidence: 200-400 mg/day of standardized extract covers the most studied range. Very low doses (<100 mg) or very high doses (>600 mg/day) fall outside the usual profile.
- Traceability and certificates of analysis: HPLC verification of rosavins and salidrosides content when available.
- Origin of the raw material: rhodiola grown under verifiable standards (origin Siberia/Altai/Scandinavia with traceability) reduces the risk of adulteration with related species or with plants that are not rhodiola.
Rhodiola in the Pleniage portfolio
Rhodiola is part of the formulation of PLENIAGE® PRO CALM+ in its form standardized to 3% rosavins, together with Albion TRAACS® magnesium bisglycinate, Ashwagandha KSM-66 BIO, L-Theanine (without EGCG) and B-group vitamins (B6, B9, B12). The rhodiola + ashwagandha combination in a single formula has a clear rationale: both adaptogens have complementary profiles (rhodiola more oriented toward mental fatigue and cognition, ashwagandha more oriented toward cortisol and sleep) and have traditionally been used in profiles of sustained stress with a mixed component. Each ingredient has individual scientific research; the specific combination of this formula has not been the subject of its own clinical trial.
This page is part of the Calm and balance cluster. To learn more about other related components, see the Ashwagandha KSM-66 page, the L-theanine page and the Magnesium bisglycinate page.
Additional contexts and pharmacological interactions to evaluate with a healthcare professional
Beyond the four critical contexts in the initial "Before you start" section, the full list of situations and interactions to evaluate with a healthcare professional includes:
- Scheduled surgery: due to its effect on the central nervous system, it is recommended to discontinue at least 2 weeks before surgery.
- History of poorly controlled arterial hypertension: caution due to the possible activating component.
- Antidepressants (especially MAOIs; with SSRIs, explicit psychiatric supervision): rhodiola has activity on monoaminergic neurotransmitters in preclinical studies. The combination requires psychiatric supervision due to theoretical risk (not frequently documented clinically, but plausible).
- Stimulants (caffeine at high doses, others): additive effect on activation.
- Antihypertensives: possible mild interference.
- Anticoagulants: mild antiplatelet activity documented in preclinical studies. Caution if combined with warfarin, acenocoumarol or antiplatelet agents.
- CYP2D6, CYP3A4 or CYP2C9 substrates: rhodiola moderately modulates some hepatic cytochromes. Consult a doctor or pharmacist if taking chronic medications metabolized by these pathways.
Frequently asked questions about rhodiola
Is rhodiola useful for stress and mental fatigue?
The largest body of clinical evidence on rhodiola in humans covers stress-related mental fatigue and cognitive performance under pressure. The Olsson 2009 trial documented improvements on validated scales of fatigue (Pines Burnout Inventory) and of concentration capacity with 576 mg/day for 28 days. The Spasov 2000 trial documented improvements in cognitive performance in students during exams. Rhodiola fits as an adaptogen oriented toward profiles where mental fatigue with a cognitive component predominates.
How does rhodiola differ from ashwagandha?
They have complementary profiles: rhodiola is more oriented toward mental fatigue and cognition under pressure, with a slightly activating component, and is taken preferably in the morning or at midday. Ashwagandha is more oriented toward cortisol, calm and sleep, without an activating component, and allows morning or evening intake (the latter if the focus is sleep). The two can be combined in profiles of sustained stress with a mixed component — that is the rationale of the PRO CALM+ formula that includes both.
Why does the 3% rosavins / 1% salidrosides standardization matter?
It is the concentration used in most published clinical trials on Rhodiola rosea and the one considered the reference in professional formulation. Other commercial rhodiolas with lower standardizations or from different species (such as Rhodiola crenulata) have different bioactive profiles, and the published clinical data are not directly extrapolable. The 3:1 ratio (rosavins:salidrosides) reflects the natural profile of R. rosea.
What is the best time of day to take rhodiola?
Morning or midday intake. Rhodiola may have a slightly activating component in some people, which is why late-evening intake is discouraged (4-6 hours before sleep). In people sensitive to stimulants it may interfere with falling asleep. The most used regimen in trials is breakfast and/or the midday meal.
How long does it take to notice the effect of rhodiola?
Effects on mental fatigue and cognition are typically documented from 2-4 weeks of continued use, according to the available clinical trials (Olsson 2009, Spasov 2000). Some people report subjective changes earlier (greater concentration capacity at 7-10 days). Rhodiola allows cycles of 8-12 weeks with rest periods of 2-4 weeks, although it has also been used in prolonged continued use in trials without relevant safety problems.
Does it have contraindications or interactions?
Yes, several relevant ones. It is contraindicated in pregnancy and breastfeeding, in bipolar disorder (theoretical risk of precipitating manic episodes through the activating component) and before scheduled surgery (discontinue at least 2 weeks before). It has potential interactions with antidepressants (especially MAOIs; with SSRIs it requires psychiatric supervision), stimulants (additive effect), antihypertensives, anticoagulants (mild antiplatelet activity) and CYP2D6/3A4/2C9 substrates. If you take chronic medication, consult your doctor before starting supplementation.
How does rhodiola fit alongside antidepressant treatment?
Rhodiola has been investigated in mild to moderate depressive presentations with positive results on validated scales (Darbinyan 2007, Mao 2015). In the Mao 2015 trial versus sertraline, both showed significant improvements; sertraline with a greater effect size, rhodiola with a better safety and tolerability profile. This positions it as a reasonable option in mild presentations under medical supervision. In moderate or severe presentations where the doctor decides the main regimen, rhodiola may be considered as an adjunct under psychiatric supervision. Discontinuing or replacing a prescribed antidepressant without psychiatric supervision is never advisable.
Rhodiola (Rhodiola rosea) is an adaptogen with traditional use in arctic regions and a large body of modern clinical research in humans on stress-related mental fatigue, cognitive performance under pressure and mild to moderate low mood. The reference standardized form is the extract at 3% rosavins and 1% salidrosides. It is a complementary tool with a favorable safety profile at the studied doses. Its best fit is in profiles where mental fatigue coexists with sustained cognitive demand, to be assessed with your reference doctor or pharmacist when there are ongoing chronic treatments.
At PLENIAGE® we publish scientific content on evidence-based supplementation. You can explore the Calm and balance cluster for more pages and related articles.
References
The statements in the article are based on available scientific literature. Below are the key verified references that support the main claims about standardized Rhodiola rosea extract.
- Olsson EM, von Schéele B, Panossian AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. 2009;75(2):105-112. PMID: 19016404.
- Spasov AA, Wikman GK, Mandrikov VB, Mironova IA, Neumoin VV. A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period. Phytomedicine. 2000;7(2):85-89. PMID: 10839209.
- Mao JJ, Xie SX, Zee J, et al. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine. 2015;22(3):394-399. PMID: 25837277.
- Edwards D, Heufelder A, Zimmermann A. Therapeutic effects and safety of Rhodiola rosea extract WS® 1375 in subjects with life-stress symptoms — results of an open-label study. Phytother Res. 2012;26(8):1220-1225. PMID: 22228617.
- Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007;61(5):343-348. PMID: 17990195.